Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety.
Explore this paper's citation graph
Summary
Grepafloxacin is an oral fluoroquinolone, with a microbiological and clinical profile that is particularly suited to the treatment of community-acquired respiratory infections, and has been well-characterised from data from over 12,000 patients treated in Phase II/III and post-marketing studies.
- Type
- article
- Published
- 1999-04-01
- Cited by
- 3
- References
- 59
- OpenAlex
- https://openalex.org/W2021382188
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:7264481
Keywords
Pharmacokinetics, Pharmacology, Medicine, Antibacterial activity, Biology
References
- Grepafloxacin: microbiological properties.
- QTc‐Interval Prolongation Associated with Slow Intravenous Erythromycin Lactobionate Infusions in Critically Ill Patients: A Prospective Evaluation and Review of the Literature
- Fortnightly Review: The pneumococcal problem
- Pharmacokinetics in vivo and pharmacodynamics ex vivo/in vitro of meropenem and cefpirome in the Yucatan micropig model: continuous infusion versus intermittent injection.
- Introduction: Evolving needs in respiratory tract infections.
- Structure of grepafloxacin relative to activity and safety profile.
- Grepafloxacin: pharmacokinetics and tissue penetration.
- Prospective study of the aetiology and outcome of pneumonia in the community.
- Postantibiotic effects of E-4868 and OPC-17116.
- Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
- Dissociated resistance among fluoroquinolones
- Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.
- Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116
- Effect of Age and Gender on the Pharmacokinetics of Grepafloxacin
- Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin
- Evaluating clinical outcomes of respiratory infection.
- In vitro activity of grepafloxacin (OPC-17116) against anaerobic bacteria.
- Antagonism of GABAA receptors by 4-quinolones.
- Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli.
- Selective antagonism of the GABAA receptor by ciprofloxacin and biphenylacetic acid
Cited by
Related papers
- Genentech taps Affimed’s antibodies
- KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria
- Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
- Use of physiological based pharmacokinetic modeling for cross-species prediction of pharmacokinetic and tissue distribution profiles of a novel niclosamide prodrug
- Effects of Animal Strain, Dose, and Cotreatment with Saikosaponin b2 on the Pharmacokinetics of Saikosaponin a in Rats
- Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters
- Pharmacokinetic modelling of pentoxifylline and lisofylline after oral and intravenous administration in mice
- Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice.